Skip to main
  1. Stocks
  2. BioCryst Pharmaceuticals
  3. Forecast
BCRX

BioCryst Pharmaceuticals (BCRX) Stock Forecast & Price Target

BioCryst Pharmaceuticals (BCRX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

BioCryst Pharma is attractive because 3Q26 revenue of $180M and non-GAAP operating profit of $53M both topped consensus, while cash and equivalents of $376M support continued pipeline execution. Orladeyo remains durable despite new HAE prophylaxis competition, with $175M in 3Q26 sales, unchanged FY26 guidance of $625M-$645M, and a pediatric pellet launch that adds an incremental growth channel with 47 prescriptions already on a YTD basis. The outlook is further strengthened by multiple catalysts, including BCX17725 top-line results by YE26 and navenibart data expected in 3Q27, which could reinforce BioCryst’s positioning in hereditary angioedema and expand the market opportunity.

Bears say

BioCryst Pharma is pressured by a high-risk development profile in which regulators may demand additional data, extend study timelines, or limit label breadth, any of which could weaken commercialization prospects. Its outlook is further constrained by intense competition in hereditary angioedema from Takhzyro and CSL Behring, with additional earlier-stage threats from Pharvaris and Intellia Therapeutics, while deucrictibant’s results were only broadly confirmatory and may still face resistance from patients already doing well on Orladeyo. Financially, the company may need additional external funding to advance its platform, and any inability to access capital markets could delay or terminate development campaigns.

BioCryst Pharmaceuticals (BCRX) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioCryst Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

BioCryst Pharmaceuticals (BCRX) Analyst Forecast & Price Prediction

Get the latest BioCryst Pharmaceuticals (BCRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BioCryst Pharmaceuticals (BCRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioCryst Pharmaceuticals (BCRX) Forecast

Analysts have given BioCryst Pharmaceuticals (BCRX) a Buy based on their latest research and market trends.

According to 7 analysts, BioCryst Pharmaceuticals (BCRX) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioCryst Pharmaceuticals (BCRX)


BioCryst Pharmaceuticals (BCRX) Analyst Forecast & Price Prediction

Get the latest BioCryst Pharmaceuticals (BCRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BioCryst Pharmaceuticals (BCRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BCRX stock data and trends